Navigation Links
AEterna Zentaris' Partner, Spectrum, Provides Update on Ozarelix in Benign Prostatic Hyperplasia
Date:4/22/2008

QUEBEC CITY, April 22 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ), a global biopharmaceutical company focused on endocrine therapy and oncology, today announced that its partner, Spectrum Pharmaceuticals (NASDAQ: SPPI), released Phase 2b results for ozarelix, a luteinizing hormone-releasing hormone (LHRH) antagonist in benign prostatic hyperplasia (BPH).

Spectrum indicated that ozarelix demonstrated sufficient clinical activity to justify its continued development in BPH. Based on these results, Spectrum is planning to submit a protocol to the FDA for the next study of ozarelix in BPH.

"We are pleased that Spectrum is proceeding with plans for their upcoming study," stated Paul Blake, M.D., Senior Vice President and Chief Medical Officer of AEterna Zentaris. "AEterna Zentaris remains committed about the potential of LHRH antagonists for BPH, particularly for our lead candidate cetrorelix, which has produced robust and consistent findings in Phase 2 trials and is currently being evaluated in three multi-center Phase 3 trials in the United States, Canada and Europe." He said that results from the cetrorelix Phase 3 program are expected in the third quarter of 2009.

About Ozarelix and Partnerships

Ozarelix is an injectable fourth generation LHRH antagonist administered as an intramuscular injection. In August 2004, AEterna Zentaris granted Spectrum Pharmaceuticals an exclusive license to develop and market ozarelix for all potential indications in North America (inc
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. AEterna Zentaris Completes Patient Recruitment for First Phase 3 Efficacy Trial with Cetrorelix in Benign Prostatic Hyperplasia
2. AEterna Zentaris Announces Changes to its Management Team
3. AEterna Zentaris and Paladin Labs Complete Sale and Purchase of Miltefosine Rights
4. Aeterna Zentaris Begins Second Phase 3 Trial of Cetrorelix for Benign Prostatic Hyperplasia
5. Aeterna Zentaris Reports Fourth Quarter and Full-Year 2007 Financial and Operating Results
6. AEterna Zentaris and Paladin Labs Announce Sale and Purchase of Miltefosine Rights
7. AEterna Zentaris Announces the Departure of SVP, Administrative and Legal Affairs
8. Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2007 Financial and Operating Results on March 5, 2008
9. AEterna Zentaris to Present at the Upcoming Roth Capital Partners 20th Annual OC Growth Stock Conference in Dana Point, California
10. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
11. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... (PRWEB) July 29, 2014 Eppendorf ... centrifugation product selection. Eppendorf 5427 R is geared towards ... DNA – it is targeted towards work requiring high ... 5427 R as it compliments their extensive 16, 48, ... line of microcentrifuge tubes, PCR tubes, PCR strip tubes, ...
(Date:7/29/2014)... Dr. Jason Wendel – recipient of a Regional Top ... Top 10 Plastic Surgeon Specialists for Nashville, TN – has ... line includes a Hydration Booster, Retexturing Night Crème, and Anti-aging ... a younger, more radiant appearance while protecting them from the ... is why at Dr. J. J. Wendel Plastic Surgery, we ...
(Date:7/29/2014)... 29, 2014 EXpressLO LLC, expert provider ... specimen preparation solutions, has been granted patent number 8,789,826 ... manipulation methods incorporating a unique specimen carrier support grid ... the second company patent for EXpressLO LLC awarded to ... , These complementary patents extend EXpressLO’s portfolio of intellectual ...
(Date:7/28/2014)... materials using light, developed by researchers at the University ... often considered the realm of science fiction, such as ... starships won,t be a reality for quite some time, ... with building blocks a few billionths of a metre ... light flies through them, and works on large chunks ...
Breaking Biology Technology:International Pipette Distributor, Pipette.com Announces the Addition of the Eppendorf Centrifuge 5427 R to Their Product Portfolio 2Dr. J. J. Wendel Launches New Line of Skin Care Products 2EXpressLO LLC Granted Second U.S. Patent for Innovative Specimen Preparation Methods 2Building 'invisible' materials with light 2
... , , ... , , Protector RNase Inhibitor ... wide known spectrum of,RNases. , Does not interfere with the performance of ... concentration) of,Protector RNase Inhibitor are needed to protect difficult RNA samples. , ...
... , , , , ... , , , , ... Polymerase for hot start PCR, was introduced,in 2000. Based on the feedback from many customers,FastStart Taq ... , , , Even the most ...
... , , , ... Increase Power and, Sensitivity in cDNA Synthesis with the new ... , , , With the new recombinant ... high sensitivity in one- or two-step RT-PCR , Obtain full-length cDNA transcripts ...
Cached Biology Technology:Protector RNase Inhibitor Enhance the Protection of,RNA against Degradation 2Challenge the Performance of Your Hot-Start PCRs,with FastStart Taq DNA Polymerase and,the Novel FastStart High Fidelity PCR System 2Transcriptor Reverse Transcriptase 2Transcriptor Reverse Transcriptase 3Transcriptor Reverse Transcriptase 4Transcriptor Reverse Transcriptase 5
(Date:7/28/2014)... Alzheimer,s disease and other forms of dementia, but the ... , University of Washington bioengineers have a designed a ... the body,s normal proteins into a state that,s linked ... Type 2 diabetes and Lou Gehrig,s disease. The synthetic ... normal state into an abnormally folded form by targeting ...
(Date:7/28/2014)... the Earth that are high priorities for conservation in ... vulnerable, as it has the lowest fraction of its ... in ,refugia, areas of biological diversity that support ... during times of great environmental change. The refugia that ... Scotland. , The biggest refugia are in the ...
(Date:7/28/2014)... that 73 percent of adult survivors of childhood cancer ... and related health problems by failing to follow a ... of the journal Cancer . , Almost 32 ... in the study had metabolic syndrome, an umbrella term ... obesity, elevated triglyceride and other abnormalities that often occur ...
Breaking Biology News(10 mins):New protein structure could help treat Alzheimer's, related diseases 2New protein structure could help treat Alzheimer's, related diseases 3Study finds Europe's habitat and wildlife is vulnerable to climate change 2Unhealthy habits more than double risk of metabolic syndrome in childhood cancer survivors 2Unhealthy habits more than double risk of metabolic syndrome in childhood cancer survivors 3
... of 35 headwater basins in the United States and Canada ... rates was less than expected in many locations, suggesting that ... change. The study was just published in a special ... Long-Term Ecological Research (LTER) network of 26 sites around the ...
... by UCLA life scientists could lead to predictions of which ... Droughts are worsening around the world, posing a great ... UCLA professor of ecology and evolutionary biology and senior author ... century how to predict which species are most vulnerable. ...
... the University of Notre Dame,s Eck Institute for Global ... identification of malaria drug resistance, an effort that will ... this devastating disease. The new discovery is described in ... of the journal Science . The team of ...
Cached Biology News:Impact of warming climate doesn't always translate to streamflow 2Which plants will survive droughts, climate change? 2Which plants will survive droughts, climate change? 3Which plants will survive droughts, climate change? 4Which plants will survive droughts, climate change? 5Notre Dame researchers using novel method to combat malaria drug resistance 2Notre Dame researchers using novel method to combat malaria drug resistance 3
Request Info...
... is able to accept cell lines produced according ... cell lines must be accompanied by a certificate ... with the requirements of cGMP and that they ... or fungi. What are the benefits of the ...
Cells are grown in triple flasks or roller bottles. Viability and growth data are generated from a parallel representative culture....
... T7Select Packaging Extracts are optimized for maximum ... insert. The high efficiency extracts (> 109 ... to produce a library containing at least ... arms. The extracts are made from a ...
Biology Products: